^
Association details:
| Biomarker: | FLT3 mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | linsitinib (ASP7487) (IGF-1R inhibitor) + NT-157 (STAT3 inhibitor, Insulin receptor substrate protein inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
IGF1R-IRS1/2 Signaling Pathway Is a Potential Target for FLT3-Mutated Acute Myeloid Leukemia
Published date:
11/06/2019
Excerpt:
Linsitinib (>5µM) and NT157 (>0.5 µM) significantly induced apoptosis in a dose-dependent manner in both cell lines (all P<0.05),…antineoplastic activity in cellular models and arises as a promising therapeutic target for FLT3-mutated AML patients.
DOI:
https://doi.org/10.1182/blood-2019-132129
